Abstract
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have